Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU

 September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 deaths from the disease. Hormone receptor positive breast cancer accounts for 65% of tumours in women aged 35 to 65 years and 82% of tumours in women older than 65 years.
Advanced Breast Cancer Naijaman's

Advanced Breast Cancer Naijaman’s

Palbociclib (Ibrance) provides a novel treatment option for women with advanced or metastatic disease. In February 2015, the American Food & Drug Administration (FDA) has granted accelerated approval for Palbociclib (Ibrance) in combination with Letrozole (Femara) for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women, followed by the February 2016  approval of Palbociclib (Ibrance) in combination with Fulvestrant (Faslodex) for the treatment of women with HR -positive, HER2 -negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

Following this, the European Medicines Agency (EMA) has now recommended granting a marketing authorisation in the European Union (EU) for Palbociclib (Ibrance) for the treatment of women with locally advanced or metastatic breast cancer. It is to be used for cancer that is HR-positive and HER2-negative. Palbociclib (Ibrance) works by blocking the activity of proteins known as cyclin-dependent kinases (CDK) 4 and 6. This inhibits the division of cancer cells and helps to stop growth of the tumour.

In postmenopausal women, Palbociclib (Ibrance) is to be used in combination with an aromatase inhibitor such as Letrozole (Femara) or with Fulvestrant (Faslodex) in cases where the patient has undergone prior hormone therapy. For women in stages preceding menopause, the hormone therapy should be combined with a luteinizing hormone releasing hormone (LHRH).

The recommendation from EMA’s Committee for Medicinal Products for Human Use (CHMP) is based on two main studies. One is a Phase III trial comparing treatment with Palbociclib (Ibrance) and Letrozole (Femara), with Letrozole (Femara) treatment alone. 444 patients who received palbociclib in this trial lived on average 24.8 months without their disease getting worse, compared to 14.5 months in the group of 222 patients that received Letrozole (Femara) alone. The other study is a Phase III trial which compared treatment of Fulvestrant (Faslodex) together with Palbociclib (Ibrance) to treatment with only Fulvestrant (Faslodex). 521 women were enrolled in this trial, regardless of their menopausal status. Preliminary results showed that 347 patients who received Palbociclib (Ibrance) had an average of 11.2 months without their disease getting worse compared to 4.6 months for 174 patients who only received Fulvestrant (Faslodex).

The most frequently reported side effects are associated with myelosuppression, a condition in which the patient’s bone marrow produces fewer blood cells than normal. Other side effects included infections, fatigue, nausea and vomiting, inflammation of the lining of the mouth (stomatitis), diarrhoea and hair loss (alopecia).

The opinion adopted by the CHMP at its September 2016 meeting is an intermediary step on Ibrance’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has been granted, a decision about price and reimbursement will then take place at the level of each Member State considering the potential role/use of the medicine in the context of the national health system of that country.

See the full announcement by the EMA here.

Tags: , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
1 Pings/Trackbacks for "Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU"

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Concealed cardiomyopathies revealed in cardiac arrest survivors September 30, 2020
    Centenary Institute researchers have discovered that genetic testing can identify "concealed cardiomyopathies" in nearly a quarter of sudden cardiac arrest (SCA) survivors who seem to have a normal heart.
  • Genetic risk of developing obesity is driven by variants that affect the brain September 29, 2020
    Some people are at higher risk of developing obesity because they possess genetic variants that affect how the brain processes sensory information and regulates feeding and behavior. The findings from scientists at the University of Copenhagen support a growing body of evidence that obesity is a disease whose roots are in the brain.
  • Inflammatory gene provides clue to obesity risk September 29, 2020
    A gene that helps to control inflammation increases the risk of obesity and could be turned off in mice to stop weight gain, a study from The University of Queensland has found.
  • Cardiac arrhythmias linked to gene mutations September 29, 2020
    Life-threatening cardiac arrhythmias can be linked to the functional and structural consequences of gene mutations. The study is published in the peer-reviewed journal Bioelectricity.
  • Secret of how fish repair their hearts could help cardiac patients September 29, 2020
    The ability of certain fish to heal damage to their hearts could lead to new treatments for patients who have suffered heart attacks and may also help to unravel how the lifestyle of our parents and grandparents can affect our own heart health.
  • Small molecule targets SARS-CoV-2 RNA for destruction September 30, 2020
    SARS-CoV-2, the virus responsible for COVID-19, has wreaked havoc on health care systems, economies and everyday lives worldwide. Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies. Now, researchers reporting in ACS Central Science have identified small molecules that target a structure within the RNA genome […]
  • Consumers who avoid products with harmful chemicals on the label have lower body burden September 30, 2020
    New research shows that paying close attention to what's in the products you buy can pay off. In a study led by Silent Spring Institute, researchers found that consumers who avoided products containing specific endocrine disruptors had significantly lower levels of the chemicals in their bodies.
  • Cannabinoids associated with negative respiratory health effects in older adults with COPD September 30, 2020
    Cannabinoids, a class of prescription pills that contain synthetically-made chemicals found in marijuana, are associated with a 64 per cent increase in death among older adults with chronic obstructive pulmonary disease (COPD), according to the first published data on the impact of cannabinoids on the respiratory health of individuals with the lung disease.
  • New study reveals how reptiles divided up the spoils in ancient seas September 30, 2020
    While dinosaurs ruled the land in the Mesozoic, the oceans were filled by predators such as crocodiles and giant lizards, but also entirely extinct groups such as ichthyosaurs and plesiosaurs. Now for the first time, researchers at the University of Bristol have modelled the changing ecologies of these great sea dragons.
  • Hackensack Meridian CDI scientists find one-two punch for preclinical cancer models September 30, 2020
    Research findings published Aug. 14, 2020 in the journal Cancer Research suggest that since some cancer treatments can be undermined by epigenetic changes (altered DNA methylation affecting gene expression) in cancer cells before the treatments are even administered, a worthwhile strategy is to administer an epigenetically-acting drug - which can pave the way for more […]
Top